A case of cardiogenic shock caused by capecitabine treatment

Nature Clinical Practice Cardiovascular Medicine

Volumn 5, Issue 11, 2008, Pages 725-729

  To, Andrew C Y ^a   Looi, Khang Li ^a   Damianovich, Dragan ^a   Taylor, Graeme B ^a   Sidebotham, David ^a   White, Harvey D ^a  

^a AUCKLAND CITY HOSPITAL   (New Zealand)

Author keywords

[No Author keywords available]

Indexed keywords

CAPECITABINE; CILAZAPRIL; DOPAMINE; IMMUNOGLOBULIN; LEVOSIMENDAN; MILRINONE; NORADRENALIN;

ABDOMINAL HYSTERECTOMY; ADJUVANT THERAPY; ADULT; ANGIOCARDIOGRAPHY; APPENDECTOMY; APPENDIX CARCINOMA; ARTICLE; CANCER STAGING; CARDIOGENIC SHOCK; CASE REPORT; CONTINUOUS INFUSION; DIARRHEA; DRUG WITHDRAWAL; ELECTROCARDIOGRAPHY; EMERGENCY WARD; FEMALE; HEART MUSCLE BIOPSY; HUMAN; LABORATORY TEST; MULTIPLE CYCLE TREATMENT; NAUSEA; PRIORITY JOURNAL; RETROSTERNAL PAIN; SALPINGOOOPHORECTOMY; TRANSTHORACIC ECHOCARDIOGRAPHY; TREATMENT OUTCOME; VOMITING;

ADENOCARCINOMA, MUCINOUS; ANTIMETABOLITES, ANTINEOPLASTIC; APPENDICEAL NEOPLASMS; BIOLOGICAL MARKERS; BIOPSY; CARDIOTONIC AGENTS; CHEMOTHERAPY, ADJUVANT; CORONARY ANGIOGRAPHY; DEOXYCYTIDINE; ECHOCARDIOGRAPHY; ELECTROCARDIOGRAPHY; FEMALE; FLUOROURACIL; HUMANS; MIDDLE AGED; SHOCK, CARDIOGENIC; TREATMENT OUTCOME;

EID: 55149091985     PISSN: 17434297     EISSN: 17434300     Source Type: Journal    
DOI: 10.1038/ncpcardio1352     Document Type: Article

References (14)

1. Becker K et al. (1999) Cardiotoxicity of the antiproliferative compound fluorouracil. Drugs 57: 475-484
2. Alter PHM et al. (2006) Cardiotoxicity of 5-fluorouracil. Cardiovasc Hematol Agents Med Chem 4: 1-5
3. Sasson Z et al. (1994) 5-Fluorouracil related toxic myocarditis: case reports and pathological confirmation. Can J Cardiol 10 861-864
4. Jensen SA et al. (2006) Risk factors and prevention of cardiotoxicity induced by 5-fluorouracil or capecitabine. Cancer Chemother Pharmacol 58: 487-493
5. Van Cutsem E et al. (2002) Incidence of cardiotoxicity with the oral fluoropyrimidine capecitabine is typical of that reported with 5-fluorouracil. Ann Oncol 13: 484-485
6. Ng M et al. (2005) The frequency and pattern of cardiotoxicity observed with capecitabine used in conjunction with oxaliplatin in patients treated for advanced colorectal cancer (CRC). Eur J Cancer 41: 1542-1546
7. Hoff PM et al. (2001) Comparison of oral capecitabine versus intravenous fluorouracil plus leucovorin as first-line treatment in 605 patients with metastatic colorectal cancer: Results of a randomized phase III study. J Clin Oncol 19: 2282-2292
8. Robben NC et al. (1993) The syndrome of 5-fluorouracil cardiotoxicity: An elusive cardiopathy. Cancer 71: 493-509
9. Meyer CC et al. (1997) Symptomatic cardiotoxicity associated with 5-fluorouracil. Pharmacotherapy 17: 729-736
10. Cardinale D et al. (2004) Prognostic value of troponin I in cardiac risk stratification of cancer patients undergoing high-dose chemotherapy. Circulation 109: 2749-2754
11. Yeh ET et al. (2004) Cardiovascular complications of cancer therapy: Diagnosis, pathogenesis, and management. Circulation 109: 3122-3131
12. Chien KR (2006) Herceptin and the heart - a molecular modifier of cardiac failure. N Engl J Med 354: 789-790
13. Cardinale D et al. (2006) Prevention of high-dose chemotherapy-induced cardiotoxicity in high-risk patients by angiotensin-converting enzyme inhibition. Circulation 114: 2474-2781
14. Merkel S et al. (2001) High-risk groups of patients with stage II colon carcinoma. Cancer 92: 1435-1443